Genomma Lab Internacional SAB de CV Announces Executive Changes
July 22, 2015
Share
Genomma Lab Internacional SAB de CV announced that Rodrigo Herrera Aspra will continue to act as Chairman of the Board of Directors and President of the Operations Committee, leaving the position of Chief Executive Officer (CEO) to Maximo Juda, who has more than 12 years of experience at Genomma Lab. Mr. Juda occupied the position of Executive Vice-President and Chief Operating Officer since December, 2014. Previous to that, he was the International Operations Vice-president and he leaded the expansion to Argentina, Brazil and the USA.
Mr. Juda holds a bachelor degree in Business Administration from the San Andres University in Argentina. This change will take effect immediately.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
